The takeaway
Kyverna Therapeutics, Inc. Common Stock shows a pronounced seasonal pattern over 2 years of data — strongest in July (+19.9%) and softest in March (−18.0%).
Right now
In July, the stock has risen 100% of years, averaging +19.9%, about +17.7 pts better than the S&P 500.
The full picture
Kyverna Therapeutics, Inc. Common Stock's most dependable month has been July, higher in 2 of 2 years; March has been its least reliable, up just 0% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | — |
Month by month
The stock's clearest edge over the S&P 500 lands in July (+17.7 pts); it has trailed the market most in March (−19.0 pts).
“vs S&P” is Kyverna Therapeutics, Inc. Common Stock’s average for a month minus the S&P 500’s average for that same month — isolating Kyverna Therapeutics, Inc. Common Stock’s own seasonal edge from broad market drift.
Reality check
Not enough recent July history to say whether the pattern still holds.
Figures are the typical (median) July return and how often it rose — the last 2 years versus the last 2(the heatmap’s default window). This verdict stays anchored to that 2-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
The seasonal story is really one month's story — July. It has closed higher in all 2 Julys, a concentration the rest of the calendar can't touch.
The strength looks broad-based rather than freakish: its average (+19.9%) and median (+19.9%) sit close together, so no single blow-out year is flattering the figure. That reliability comes with real swings, mind — even July ranges by 9.0% from year to year, so any single year can land far from the average. Better still, that strength is the stock's own and not just a buoyant market — July has outpaced the S&P 500 by +17.7 points on average. Few peers keep such company in July — the typical stock clears it just 61% of the time.
It doesn't stand entirely alone — August, October, and November have leaned firm as well, if less emphatically. On the other side of the ledger, March has been the soft spot — the weakest of 7 months that average a loss (−18.0%), and the edge isn't year-round — the stock has trailed the S&P 500 in March, January, and June. Its roughest month on record was a −42.6% June in 2024 — a reminder of how hard even a seasonal name can fall.
For a stock this dependable in July, the sharper question is the rest of the year — outside its strong stretch, the calendar gives far less to lean on. With a short 2-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (July), its worst (March), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2024 its best month (July, +19.9%) has run well ahead of its worst (March, −18.0%) — the heatmap above shows how steady that gap has been year to year.
July has been the strongest, averaging +19.9% and closing higher in all 2 years on record since 2024.
It's the weakest, averaging −18.0% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade